Expression of gsk3, pick1, nefl, C4, nkcc1 and synaptophysin in peripheral blood mononuclear cells of the first-episode schizophrenia patients
For recovery enhancement, performance optimisation, or longevity goals in healthy people, until a randomised, placebo-controlled trial in a defined population with an objective primary endpoint and pharmacovigilance over a clinically meaningful duration produces data we do not currently have, we just don't have good evidence of benefit, let alone safety
Age-Related Dosing Modifications Clinical trials have primarily enrolled adults aged 18-75, with most participants in the 30-60 age range
Common benefits include increased energy, enhanced focus, and better metabolism